Q32 Bio to present 36-week Phase 2a SIGNAL-AA trial data for bempikibart in alopecia areata at EADV 2026
QTTB•QTTB•QTTB•QTTB•Q32 Bio flagged new 36-week results from its Phase 2a SIGNAL-AA Part B trial of bempikibart in severe alopecia areata.
The trial readout indicates hair regrowth that persisted after treatment stopped, supporting bempikibart’s potential as a differentiated immune-targeting therapy.
Data will be presented at the EADV Congress in Vienna on Sept. 30, 2026, including early findings from a 16-week off-drug period.
